Technical Analysis for LXEO - Lexeo Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 14.26 | 3.90% | 0.54 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 3.90% | |
| Weak + Overbought | Other | 3.90% | |
| Above Upper BB | Strength | 3.90% | |
| Overbought Stochastic | Strength | 3.90% | |
| Up 3 Days in a Row | Strength | 3.90% | |
| Up 4 Days in a Row | Strength | 3.90% | |
| Up 5 Days in a Row | Strength | 3.90% | |
| Upper Bollinger Band Touch | Strength | 3.90% | |
| Stochastic Reached Overbought | Strength | 6.14% | |
| Weak + Overbought | Other | 6.14% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 12 minutes ago |
| Up 3% | 12 minutes ago |
| 60 Minute Opening Range Breakout | 42 minutes ago |
| Rose Above 50 DMA | 42 minutes ago |
| Up 2% | 42 minutes ago |
Get a Trading Sidekick!
- Earnings date: 02/28/2024
Lexeo Therapeutics, Inc. Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.33 |
| 52 Week Low | 9.0 |
| Average Volume | 131,032 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 13.82 |
| 20-Day Moving Average | 12.53 |
| 10-Day Moving Average | 12.73 |
| Average True Range | 0.86 |
| RSI (14) | 57.26 |
| ADX | 16.09 |
| +DI | 24.63 |
| -DI | 14.29 |
| Chandelier Exit (Long, 3 ATRs) | 12.48 |
| Chandelier Exit (Short, 3 ATRs) | 14.15 |
| Upper Bollinger Bands | 13.46 |
| Lower Bollinger Band | 11.60 |
| Percent B (%b) | 1.14 |
| BandWidth | 14.87 |
| MACD Line | -0.17 |
| MACD Signal Line | -0.42 |
| MACD Histogram | 0.2504 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.12 | ||||
| Resistance 3 (R3) | 15.06 | 14.53 | 14.88 | ||
| Resistance 2 (R2) | 14.53 | 14.18 | 14.56 | 14.80 | |
| Resistance 1 (R1) | 14.13 | 13.96 | 14.33 | 14.19 | 14.73 |
| Pivot Point | 13.60 | 13.60 | 13.71 | 13.63 | 13.60 |
| Support 1 (S1) | 13.20 | 13.25 | 13.40 | 13.26 | 12.71 |
| Support 2 (S2) | 12.67 | 13.03 | 12.70 | 12.64 | |
| Support 3 (S3) | 12.27 | 12.67 | 12.56 | ||
| Support 4 (S4) | 12.33 |
